MX2024008821A - Formas solidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparacion de las mismas. - Google Patents
Formas solidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparacion de las mismas.Info
- Publication number
- MX2024008821A MX2024008821A MX2024008821A MX2024008821A MX2024008821A MX 2024008821 A MX2024008821 A MX 2024008821A MX 2024008821 A MX2024008821 A MX 2024008821A MX 2024008821 A MX2024008821 A MX 2024008821A MX 2024008821 A MX2024008821 A MX 2024008821A
- Authority
- MX
- Mexico
- Prior art keywords
- helicase
- crystalline forms
- solid crystalline
- preparation
- primase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22151820 | 2022-01-17 | ||
| EP22170332 | 2022-04-27 | ||
| PCT/EP2023/050883 WO2023135303A1 (en) | 2022-01-17 | 2023-01-16 | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008821A true MX2024008821A (es) | 2024-07-29 |
Family
ID=84982261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008821A MX2024008821A (es) | 2022-01-17 | 2023-01-16 | Formas solidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparacion de las mismas. |
Country Status (12)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4580601A1 (en) * | 2022-08-29 | 2025-07-09 | Assembly Biosciences, Inc. | Pharmaceutical compositions for herpes virus |
| IL325911A (en) | 2023-07-17 | 2026-03-01 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| PH12018501979B1 (en) | 2016-04-06 | 2023-05-05 | Innovative Molecules Gmbh | Aminothiazole derivatives useful as antiviral agents |
| PL3692039T3 (pl) | 2017-10-05 | 2023-04-17 | Innovative Molecules Gmbh | Enancjomery podstawionych tiazoli jako związki przeciwwirusowe |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| AU2021367976A1 (en) | 2020-10-29 | 2023-06-08 | Innovative Molecules Gmbh | Deuterated aminothiazole compounds as antiviral compounds |
-
2023
- 2023-01-16 PY PY202302302301A patent/PY2302301A/es unknown
- 2023-01-16 US US18/729,411 patent/US20250115565A1/en active Pending
- 2023-01-16 KR KR1020247027250A patent/KR20240134979A/ko active Pending
- 2023-01-16 EP EP23700877.6A patent/EP4466255A1/en active Pending
- 2023-01-16 WO PCT/EP2023/050883 patent/WO2023135303A1/en not_active Ceased
- 2023-01-16 JP JP2024542125A patent/JP2025502300A/ja active Pending
- 2023-01-16 UY UY0001040111A patent/UY40111A/es unknown
- 2023-01-16 CA CA3246779A patent/CA3246779A1/en active Pending
- 2023-01-16 MX MX2024008821A patent/MX2024008821A/es unknown
- 2023-01-16 AU AU2023206628A patent/AU2023206628A1/en active Pending
- 2023-01-16 IL IL314188A patent/IL314188A/en unknown
-
2024
- 2024-07-15 CL CL2024002124A patent/CL2024002124A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024002124A1 (es) | 2024-11-22 |
| IL314188A (en) | 2024-09-01 |
| UY40111A (es) | 2023-08-15 |
| PY2302301A (es) | 2023-10-31 |
| US20250115565A1 (en) | 2025-04-10 |
| WO2023135303A1 (en) | 2023-07-20 |
| CA3246779A1 (en) | 2023-07-20 |
| TW202337444A (zh) | 2023-10-01 |
| EP4466255A1 (en) | 2024-11-27 |
| KR20240134979A (ko) | 2024-09-10 |
| AU2023206628A1 (en) | 2024-08-01 |
| JP2025502300A (ja) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| CR20230261A (es) | Cocristal de un inhibidor de cdk | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| EP4374858A3 (en) | Benzimidazolone derived inhibitors of bcl6 | |
| CR20230382A (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| TNSN06228A1 (en) | Compounds and methods of use | |
| WO2023205463A8 (en) | Heteroaryl compounds for the treatment of pain | |
| ZA202208541B (en) | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof | |
| MX2025006384A (es) | Formas cristalinas de un inhibidor de trpc de piridazinona | |
| UY40111A (es) | Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas | |
| JOP20250051A1 (ar) | مُعدِّلات مضاد تربسين ألفا-1 | |
| IL172419A0 (en) | Piperazine derivatives and methods of use | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| WO2023196720A3 (en) | Lrrk2 inhibitors | |
| EP4480538A3 (en) | Solid state forms of mavacamten and process for preparation thereof | |
| WO2024006292A3 (en) | Methods of treating cancer | |
| WO2024023262A3 (en) | Nucleic acid compounds | |
| WO2024026483A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2024026479A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2024026486A3 (en) | Cdk2 inhibitors and methods of using the same | |
| MX2024015077A (es) | Benzopirimidina-4(3h)-onas como inhibidores de pi3k | |
| MX2026000476A (es) | Sales clorhidrato cristalinas micronizadas de compuestos inhibidores antiviricos de la helicasa-primasa | |
| MX2025014397A (es) | Inhibidores de helicasa de adn recq del sindrome de werner (wrn) |